Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 [ingenol mebutate] 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Superficial Basal Cell Carcinoma
Latest Information Update: 16 Mar 2011
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions
- 18 Jul 2006 Status change
- 06 Sep 2005 New trial record.